Moxonidine for Prevention of Post-ablation AFib Recurrences
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 150 participants.
Also called NCT01791699
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 150 participants
- Sponsor
- Spyridon Deftereos
- Registry
-
NCT01791699
-
- Other papers using this trial's data
- Amino-terminal B-natriuretic peptide levels and postablation recurrence in hypertensive patients with paroxysmal atrial fibrillation
- Central sympathetic inhibition to reduce postablation atrial fibrillation recurrences in hypertensive patients: a randomized, controlled study
- Effect of Postablation Statin Treatment on Arrhythmia Recurrence in Patients With Paroxysmal Atrial Fibrillation
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Greece
- Registry status
- Completed
Technical summary
Registry record NCT01791699. Randomized; quadruple masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2013-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Moxonidine for Prevention of Post-ablation AFib Recurrences
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Moxonidine
- Intervention (Drug)
- Placebo
- Lead sponsor
- Spyridon Deftereos
Record details
- Record id
cardio:ct-nct01791699- Content hash
4cd45a6faedcc1f1a68c1aae9326b30b77bdfab226fa07455c66ca64717da94f